GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Operating Margin %

Vivos (RDGL) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Vivos Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Vivos's Operating Income for the three months ended in Dec. 2023 was $-0.94 Mil. Vivos's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Vivos's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Vivos's Operating Margin % or its related term are showing as below:

RDGL' s Operating Margin % Range Over the Past 10 Years
Min: -65425   Med: -13300   Max: -6994.44
Current: -13965


RDGL's Operating Margin % is ranked worse than
98.65% of 813 companies
in the Medical Devices & Instruments industry
Industry Median: 1.27 vs RDGL: -13965.00

Vivos's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Vivos's Operating Income for the three months ended in Dec. 2023 was $-0.94 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.79 Mil.


Vivos Operating Margin % Historical Data

The historical data trend for Vivos's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Operating Margin % Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,300.00 -9,614.29 -16,680.00 -6,994.44 -13,965.00

Vivos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,766.67 -4,133.33 -13,057.14 -9,828.57 -

Competitive Comparison of Vivos's Operating Margin %

For the Medical Devices subindustry, Vivos's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Vivos's Operating Margin % falls into.



Vivos Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Vivos's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-2.793 / 0.02
=-13,965.00 %

Vivos's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.943 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos  (OTCPK:RDGL) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vivos Operating Margin % Related Terms

Thank you for viewing the detailed overview of Vivos's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos (RDGL) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336